Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service thrombectomy, IVC filters & venous stents cases in Ohio: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (194 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 17 | 1,669 | 47% |
| 2020 | 13 | 1,522 | 50% |
| 2021 | 14 | 1,707 | 53% |
| 2022 | 13 | 1,569 | 56% |
| 2023 | 9 | 1,407 | 58% |
| 2024 | 6 | 1,351 | 60% |
| 2025 from claims | – | 1,416 1,300–1,498 | 61% |
| 2026 forecast | – | 1,454 1,280–1,678 | 61% |
| 2027 forecast | – | 1,459 1,247–1,739 | 61% |
| 2028 forecast | – | 1,463 1,221–1,792 | 61% |
| 2029 forecast | – | 1,468 1,199–1,841 | 62% |
| 2030 forecast | – | 1,472 1,179–1,886 | 62% |
Mechanical thrombectomy, IVC filter placement, and iliac venous stenting. Professional codes (what the surgeon bills): CPT 37187, 37184, 37191, 37238.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Ohio; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 93% inpatient hospital, 7% hospital outpatient. The share outside the hospital has moved −2 pts since 2019.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 28 | 2,235+1.2%/yr | +1.2%/yr | 1.6 | 18% | 3,030 in 2030+5.2%/yr |
| Michigan | 10 | 1,534−1.8%/yr | −1.8%/yr | 1.8 | 18% | 1,770 in 2030+2.4%/yr |
| Indiana | 7 | 1,264+6.5%/yr | +6.5%/yr | 1.8 | 15% | 1,940 in 2030+7.4%/yr |
| Missouri | 8 | 855−5.5%/yr | −5.5%/yr | 1.4 | 0% | 790 in 2030−1.3%/yr |
| Wisconsin | 1 | 601−4.2%/yr | −4.2%/yr | 1.1 | 5% | 1,010 in 2030+9.1%/yr |
| Minnesota | 3 | 534−2.8%/yr | −2.8%/yr | 1.2 | 0% | 1,150 in 2030+14%/yr |
| Kansas | 2 | 454+4.3%/yr | +4.3%/yr | 1.1 | 0% | 920 in 2030+12%/yr |
| South Dakota | 6 | 318+3.2%/yr | +3.2%/yr | 2.5 | 0% | 220 in 2030−5.7%/yr |
| Iowa | 1 | 3090%/yr | 0%/yr | 0.7 | 0% | 490 in 2030+8.2%/yr |
| Nebraska | 1 | 272−1.9%/yr | −1.9%/yr | 1.1 | 0% | 220 in 2030−3.7%/yr |
| North Dakota | 1 | 126−1.2%/yr | −1.2%/yr | 1.3 | 0% | 260 in 2030+13%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Dialysis access | 46 | 4,014−15%/yr | −15%/yr | 3.80.8× | 68% | 3,930 in 2030−0.4%/yr |
| Peripheral arterial intervention | 26 | 3,751−11%/yr | −11%/yr | 3.20.7× | 4% | 3,700 in 2030−0.2%/yr |
| Superficial venous ablation | 47 | 3,475−3.2%/yr | −3.2%/yr | 3.00.9× | 79% | 4,520 in 2030+4.5%/yr |
| Carotid revascularization | 18 | 1,238−6.8%/yr | −6.8%/yr | 1.10.9× | 0% | 1,200 in 2030−0.6%/yr |
| Aortic endografts (EVAR/TEVAR) | 3 | 615−5.9%/yr | −5.9%/yr | 0.61.2× | 0% | 460 in 2030−4.8%/yr |
Thrombectomy, IVC filters & venous stents in every state, and its device makers · Every procedure market in Ohio · Every state · Compare with Illinois
Surmodics leads with 41% of company spending on these surgeons in 2025, +10 pts on 2024.
In 2025, 13 companies reported engagement with Ohio’s surgeons worth $398K in consulting, speaking, meals and travel tied to these products, about $66K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 22 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.